ID   UBP33_HUMAN             Reviewed;         942 AA.
AC   Q8TEY7; Q8TEY6; Q96AV6; Q9H9F0; Q9UPQ5;
DT   10-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   15-MAR-2017, entry version 148.
DE   RecName: Full=Ubiquitin carboxyl-terminal hydrolase 33;
DE            EC=3.4.19.12;
DE   AltName: Full=Deubiquitinating enzyme 33;
DE   AltName: Full=Ubiquitin thioesterase 33;
DE   AltName: Full=Ubiquitin-specific-processing protease 33;
DE   AltName: Full=VHL-interacting deubiquitinating enzyme 1;
DE            Short=hVDU1;
GN   Name=USP33; Synonyms=KIAA1097, VDU1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), UBIQUITINATION,
RP   INTERACTION WITH VHL, AND TISSUE SPECIFICITY.
RX   PubMed=11739384; DOI=10.1074/jbc.M108269200;
RA   Li Z., Na X., Wang D., Schoen S.R., Messing E.M., Wu G.;
RT   "Ubiquitination of a novel deubiquitinating enzyme requires direct
RT   binding to von Hippel-Lindau tumor suppressor protein.";
RL   J. Biol. Chem. 277:4656-4662(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=10470851; DOI=10.1093/dnares/6.3.197;
RA   Kikuno R., Nagase T., Ishikawa K., Hirosawa M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIV.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 6:197-205(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, AND INTERACTION WITH DIO2.
RX   PubMed=12865408; DOI=10.1172/JCI18348;
RA   Curcio-Morelli C., Zavacki A.M., Christofollete M., Gereben B.,
RA   de Freitas B.C., Harney J.W., Li Z., Wu G., Bianco A.C.;
RT   "Deubiquitination of type 2 iodothyronine deiodinase by von Hippel-
RT   Lindau protein-interacting deubiquitinating enzymes regulates thyroid
RT   hormone activation.";
RL   J. Clin. Invest. 112:189-196(2003).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-439, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   INTERACTION WITH SELENBP1, AND SUBCELLULAR LOCATION.
RX   PubMed=19118533; DOI=10.1016/j.bbrc.2008.12.110;
RA   Jeong J.Y., Wang Y., Sytkowski A.J.;
RT   "Human selenium binding protein-1 (hSP56) interacts with VDU1 in a
RT   selenium-dependent manner.";
RL   Biochem. Biophys. Res. Commun. 379:583-588(2009).
RN   [9]
RP   FUNCTION, INTERACTION WITH ADRB2, AND MUTAGENESIS OF CYS-194 AND
RP   HIS-673.
RX   PubMed=19424180; DOI=10.1038/emboj.2009.128;
RA   Berthouze M., Venkataramanan V., Li Y., Shenoy S.K.;
RT   "The deubiquitinases USP33 and USP20 coordinate beta2 adrenergic
RT   receptor recycling and resensitization.";
RL   EMBO J. 28:1684-1696(2009).
RN   [10]
RP   FUNCTION, INTERACTION WITH ARRB1 AND ARRB2, AND MUTAGENESIS OF CYS-194
RP   AND HIS-673.
RX   PubMed=19363159; DOI=10.1073/pnas.0901083106;
RA   Shenoy S.K., Modi A.S., Shukla A.K., Xiao K., Berthouze M., Ahn S.,
RA   Wilkinson K.D., Miller W.E., Lefkowitz R.J.;
RT   "Beta-arrestin-dependent signaling and trafficking of 7-transmembrane
RT   receptors is reciprocally regulated by the deubiquitinase USP33 and
RT   the E3 ligase Mdm2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:6650-6655(2009).
RN   [11]
RP   ALTERNATIVE SPLICING (ISOFORM 3), AND SUBCELLULAR LOCATION.
RX   PubMed=21801292; DOI=10.1111/j.1600-0854.2011.01261.x;
RA   Thorne C., Eccles R.L., Coulson J.M., Urbe S., Clague M.J.;
RT   "Isoform-specific localization of the deubiquitinase USP33 to the
RT   Golgi apparatus.";
RL   Traffic 12:1563-1574(2011).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CCP110, DEVELOPMENTAL
RP   STAGE, AND MUTAGENESIS OF CYS-194 AND HIS-673.
RX   PubMed=23486064; DOI=10.1038/nature11941;
RA   Li J., D'Angiolella V., Seeley E.S., Kim S., Kobayashi T., Fu W.,
RA   Campos E.I., Pagano M., Dynlacht B.D.;
RT   "USP33 regulates centrosome biogenesis via deubiquitination of the
RT   centriolar protein CP110.";
RL   Nature 495:255-259(2013).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   STRUCTURE BY NMR OF 36-130, ZINC-BINDING, AND DOMAIN UBP-TYPE ZINC
RP   FINGER.
RX   PubMed=17766394; DOI=10.1110/ps.072967807;
RA   Allen M.D., Bycroft M.;
RT   "The solution structure of the ZnF UBP domain of USP33/VDU1.";
RL   Protein Sci. 16:2072-2075(2007).
CC   -!- FUNCTION: Deubiquitinating enzyme involved in various processes
CC       such as centrosome duplication, cellular migration and beta-2
CC       adrenergic receptor/ADRB2 recycling. Involved in regulation of
CC       centrosome duplication by mediating deubiquitination of CCP110 in
CC       S and G2/M phase, leading to stabilize CCP110 during the period
CC       which centrioles duplicate and elongate. Involved in cell
CC       migration via its interaction with intracellular domain of ROBO1,
CC       leading to regulate the Slit signaling. Plays a role in
CC       commissural axon guidance cross the ventral midline of the neural
CC       tube in a Slit-dependent manner, possibly by mediating the
CC       deubiquitination of ROBO1. Acts as a regulator of G-protein
CC       coupled receptor (GPCR) signaling by mediating the
CC       deubiquitination of beta-arrestins (ARRB1 and ARRB2) and beta-2
CC       adrenergic receptor (ADRB2). Plays a central role in ADRB2
CC       recycling and resensitization after prolonged agonist stimulation
CC       by constitutively binding ADRB2, mediating deubiquitination of
CC       ADRB2 and inhibiting lysosomal trafficking of ADRB2. Upon
CC       dissociation, it is probably transferred to the translocated beta-
CC       arrestins, leading to beta-arrestins deubiquitination and
CC       disengagement from ADRB2. This suggests the existence of a dynamic
CC       exchange between the ADRB2 and beta-arrestins. Deubiquitinates
CC       DIO2, thereby regulating thyroid hormone regulation. Mediates
CC       deubiquitination of both 'Lys-48'- and 'Lys-63'-linked
CC       polyubiquitin chains. {ECO:0000269|PubMed:12865408,
CC       ECO:0000269|PubMed:19363159, ECO:0000269|PubMed:19424180,
CC       ECO:0000269|PubMed:23486064}.
CC   -!- CATALYTIC ACTIVITY: Thiol-dependent hydrolysis of ester,
CC       thioester, amide, peptide and isopeptide bonds formed by the C-
CC       terminal Gly of ubiquitin (a 76-residue protein attached to
CC       proteins as an intracellular targeting signal).
CC   -!- SUBUNIT: Interacts with VHL, leading to its ubiquitination and
CC       subsequent degradation. Interacts with ARRB1, ARRB2, ADRB2, DIO2
CC       and ROBO1. Interacts with SELENBP1; in a selenium-dependent
CC       manner. Interacts with CCP110. {ECO:0000269|PubMed:11739384,
CC       ECO:0000269|PubMed:12865408, ECO:0000269|PubMed:19118533,
CC       ECO:0000269|PubMed:19363159, ECO:0000269|PubMed:19424180,
CC       ECO:0000269|PubMed:23486064}.
CC   -!- INTERACTION:
CC       Q13228:SELENBP1; NbExp=5; IntAct=EBI-719307, EBI-711619;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, perinuclear region
CC       {ECO:0000269|PubMed:19118533}. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome
CC       {ECO:0000269|PubMed:23486064}. Note=Associates with centrosomes
CC       predominantly in S and G2 phases but less in G1 phase
CC       (PubMed:23486064). {ECO:0000269|PubMed:23486064}.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Golgi apparatus
CC       {ECO:0000269|PubMed:21801292}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q8TEY7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8TEY7-2; Sequence=VSP_008591;
CC       Name=3;
CC         IsoId=Q8TEY7-3; Sequence=VSP_008592, VSP_008593, VSP_008594;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC       {ECO:0000269|PubMed:11739384}.
CC   -!- DEVELOPMENTAL STAGE: Increased expression in S and early G2 phases
CC       and lower levels in late G2 and M phases.
CC       {ECO:0000269|PubMed:23486064}.
CC   -!- DOMAIN: The UBP-type zinc finger binds 3 zinc ions. However, it
CC       does not bind ubiquitin, probably because the conserved Arg in
CC       position 86 is replaced by a Glu residue.
CC       {ECO:0000269|PubMed:17766394}.
CC   -!- PTM: Ubiquitinated via a VHL-dependent pathway for proteasomal
CC       degradation. {ECO:0000269|PubMed:11739384}.
CC   -!- SIMILARITY: Belongs to the peptidase C19 family. USP20/USP33
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA83049.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF383172; AAL78314.1; -; mRNA.
DR   EMBL; AF383173; AAL78315.1; -; mRNA.
DR   EMBL; AB029020; BAA83049.1; ALT_INIT; mRNA.
DR   EMBL; AK022864; BAB14279.1; -; mRNA.
DR   EMBL; AC114487; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC016663; AAH16663.1; -; mRNA.
DR   CCDS; CCDS678.1; -. [Q8TEY7-1]
DR   CCDS; CCDS679.1; -. [Q8TEY7-2]
DR   CCDS; CCDS680.1; -. [Q8TEY7-3]
DR   RefSeq; NP_055832.3; NM_015017.4. [Q8TEY7-1]
DR   RefSeq; NP_963918.1; NM_201624.2. [Q8TEY7-2]
DR   RefSeq; NP_963920.1; NM_201626.2. [Q8TEY7-3]
DR   UniGene; Hs.480597; -.
DR   PDB; 2UZG; NMR; -; A=36-130.
DR   PDBsum; 2UZG; -.
DR   ProteinModelPortal; Q8TEY7; -.
DR   SMR; Q8TEY7; -.
DR   BioGrid; 116671; 47.
DR   DIP; DIP-48942N; -.
DR   IntAct; Q8TEY7; 8.
DR   MINT; MINT-1370210; -.
DR   STRING; 9606.ENSP00000350009; -.
DR   MEROPS; C19.037; -.
DR   iPTMnet; Q8TEY7; -.
DR   PhosphoSitePlus; Q8TEY7; -.
DR   BioMuta; USP33; -.
DR   DMDM; 116242838; -.
DR   EPD; Q8TEY7; -.
DR   MaxQB; Q8TEY7; -.
DR   PaxDb; Q8TEY7; -.
DR   PeptideAtlas; Q8TEY7; -.
DR   PRIDE; Q8TEY7; -.
DR   DNASU; 23032; -.
DR   Ensembl; ENST00000357428; ENSP00000350009; ENSG00000077254. [Q8TEY7-1]
DR   Ensembl; ENST00000370792; ENSP00000359828; ENSG00000077254. [Q8TEY7-3]
DR   Ensembl; ENST00000370793; ENSP00000359829; ENSG00000077254. [Q8TEY7-1]
DR   Ensembl; ENST00000370794; ENSP00000359830; ENSG00000077254. [Q8TEY7-2]
DR   GeneID; 23032; -.
DR   KEGG; hsa:23032; -.
DR   UCSC; uc001dht.5; human. [Q8TEY7-1]
DR   CTD; 23032; -.
DR   DisGeNET; 23032; -.
DR   GeneCards; USP33; -.
DR   H-InvDB; HIX0159957; -.
DR   HGNC; HGNC:20059; USP33.
DR   HPA; HPA005719; -.
DR   MIM; 615146; gene.
DR   neXtProt; NX_Q8TEY7; -.
DR   OpenTargets; ENSG00000077254; -.
DR   PharmGKB; PA134955343; -.
DR   eggNOG; ENOG410IN4T; Eukaryota.
DR   eggNOG; ENOG410ZG0F; LUCA.
DR   GeneTree; ENSGT00860000133682; -.
DR   HOGENOM; HOG000286031; -.
DR   HOVERGEN; HBG054196; -.
DR   InParanoid; Q8TEY7; -.
DR   KO; K11848; -.
DR   OMA; ICNKINK; -.
DR   OrthoDB; EOG091G02UV; -.
DR   PhylomeDB; Q8TEY7; -.
DR   TreeFam; TF352179; -.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   ChiTaRS; USP33; human.
DR   EvolutionaryTrace; Q8TEY7; -.
DR   GeneWiki; USP33; -.
DR   GenomeRNAi; 23032; -.
DR   PRO; PR:Q8TEY7; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000077254; -.
DR   CleanEx; HS_USP33; -.
DR   ExpressionAtlas; Q8TEY7; baseline and differential.
DR   Genevisible; Q8TEY7; HS.
DR   GO; GO:0044297; C:cell body; IEA:Ensembl.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; IDA:HPA.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0030891; C:VCB complex; TAS:UniProtKB.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IMP:UniProtKB.
DR   GO; GO:0001664; F:G-protein coupled receptor binding; IPI:UniProtKB.
DR   GO; GO:0017160; F:Ral GTPase binding; IPI:UniProtKB.
DR   GO; GO:0004843; F:thiol-dependent ubiquitin-specific protease activity; IDA:UniProtKB.
DR   GO; GO:0036459; F:thiol-dependent ubiquitinyl hydrolase activity; TAS:Reactome.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; ISS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; ISS:UniProtKB.
DR   GO; GO:0009267; P:cellular response to starvation; IDA:UniProtKB.
DR   GO; GO:0051298; P:centrosome duplication; IMP:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0032091; P:negative regulation of protein binding; IMP:UniProtKB.
DR   GO; GO:0032092; P:positive regulation of protein binding; IMP:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; IDA:UniProtKB.
DR   GO; GO:0071108; P:protein K48-linked deubiquitination; IDA:UniProtKB.
DR   GO; GO:0070536; P:protein K63-linked deubiquitination; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IMP:CACAO.
DR   GO; GO:0010506; P:regulation of autophagy; IMP:UniProtKB.
DR   GO; GO:0008277; P:regulation of G-protein coupled receptor protein signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; TAS:UniProtKB.
DR   Gene3D; 3.30.2230.10; -; 2.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR006615; Pept_C19_DUSP.
DR   InterPro; IPR001394; Peptidase_C19_UCH.
DR   InterPro; IPR018200; USP_CS.
DR   InterPro; IPR028889; USP_dom.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR001607; Znf_UBP.
DR   Pfam; PF06337; DUSP; 2.
DR   Pfam; PF00443; UCH; 1.
DR   Pfam; PF02148; zf-UBP; 1.
DR   SMART; SM00695; DUSP; 2.
DR   SMART; SM00290; ZnF_UBP; 1.
DR   SUPFAM; SSF143791; SSF143791; 2.
DR   PROSITE; PS51283; DUSP; 2.
DR   PROSITE; PS00972; USP_1; 1.
DR   PROSITE; PS00973; USP_2; 1.
DR   PROSITE; PS50235; USP_3; 1.
DR   PROSITE; PS50271; ZF_UBP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Cytoskeleton; Endocytosis; Golgi apparatus; Hydrolase; Metal-binding;
KW   Phosphoprotein; Protease; Reference proteome; Repeat; Thiol protease;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    942       Ubiquitin carboxyl-terminal hydrolase 33.
FT                                /FTId=PRO_0000080664.
FT   DOMAIN      185    715       USP.
FT   DOMAIN      717    810       DUSP 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00613}.
FT   DOMAIN      818    921       DUSP 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00613}.
FT   ZN_FING      59    123       UBP-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00502}.
FT   ACT_SITE    194    194       Nucleophile.
FT   ACT_SITE    673    673       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10092, ECO:0000255|PROSITE-
FT                                ProRule:PRU10093}.
FT   MOD_RES     377    377       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     439    439       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   VAR_SEQ       1     31       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10470851,
FT                                ECO:0000303|PubMed:11739384}.
FT                                /FTId=VSP_008591.
FT   VAR_SEQ     552    559       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_008592.
FT   VAR_SEQ     834    836       LNR -> VKK (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_008593.
FT   VAR_SEQ     837    942       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_008594.
FT   MUTAGEN     194    194       C->S: Abolishes deubiquitinating
FT                                activity. Does not inhibit lysosomal
FT                                trafficking of ADRB2; when associated
FT                                with Q-673. {ECO:0000269|PubMed:19363159,
FT                                ECO:0000269|PubMed:19424180,
FT                                ECO:0000269|PubMed:23486064}.
FT   MUTAGEN     673    673       H->Q: Abolishes deubiquitinating
FT                                activity. Does not inhibit lysosomal
FT                                trafficking of ADRB2; when associated
FT                                with S-194. {ECO:0000269|PubMed:19363159,
FT                                ECO:0000269|PubMed:19424180,
FT                                ECO:0000269|PubMed:23486064}.
FT   CONFLICT    241    241       H -> Y (in Ref. 1; AAL78314/AAL78315 and
FT                                2; BAA83049). {ECO:0000305}.
FT   CONFLICT    428    428       S -> L (in Ref. 3; BAB14279).
FT                                {ECO:0000305}.
FT   CONFLICT    617    617       K -> R (in Ref. 3; BAB14279).
FT                                {ECO:0000305}.
FT   HELIX        40     44       {ECO:0000244|PDB:2UZG}.
FT   HELIX        50     56       {ECO:0000244|PDB:2UZG}.
FT   TURN         57     59       {ECO:0000244|PDB:2UZG}.
FT   STRAND       62     64       {ECO:0000244|PDB:2UZG}.
FT   STRAND       72     74       {ECO:0000244|PDB:2UZG}.
FT   TURN         86     89       {ECO:0000244|PDB:2UZG}.
FT   HELIX        91     98       {ECO:0000244|PDB:2UZG}.
FT   STRAND      103    106       {ECO:0000244|PDB:2UZG}.
FT   TURN        107    110       {ECO:0000244|PDB:2UZG}.
FT   STRAND      111    114       {ECO:0000244|PDB:2UZG}.
FT   TURN        115    118       {ECO:0000244|PDB:2UZG}.
FT   STRAND      119    121       {ECO:0000244|PDB:2UZG}.
SQ   SEQUENCE   942 AA;  106727 MW;  10A3AD632B901A74 CRC64;
     MTGSNSHITI LTLKVLPHFE SLGKQEKIPN KMSAFRNHCP HLDSVGEITK EDLIQKSLGT
     CQDCKVQGPN LWACLENRCS YVGCGESQVD HSTIHSQETK HYLTVNLTTL RVWCYACSKE
     VFLDRKLGTQ PSLPHVRQPH QIQENSVQDF KIPSNTTLKT PLVAVFDDLD IEADEEDELR
     ARGLTGLKNI GNTCYMNAAL QALSNCPPLT QFFLDCGGLA RTDKKPAICK SYLKLMTELW
     HKSRPGSVVP TTLFQGIKTV NPTFRGYSQQ DAQEFLRCLM DLLHEELKEQ VMEVEEDPQT
     ITTEETMEED KSQSDVDFQS CESCSNSDRA ENENGSRCFS EDNNETTMLI QDDENNSEMS
     KDWQKEKMCN KINKVNSEGE FDKDRDSISE TVDLNNQETV KVQIHSRASE YITDVHSNDL
     STPQILPSNE GVNPRLSASP PKSGNLWPGL APPHKKAQSA SPKRKKQHKK YRSVISDIFD
     GTIISSVQCL TCDRVSVTLE TFQDLSLPIP GKEDLAKLHS SSHPTSIVKA GSCGEAYAPQ
     GWIAFFMEYV KRFVVSCVPS WFWGPVVTLQ DCLAAFFARD ELKGDNMYSC EKCKKLRNGV
     KFCKVQNFPE ILCIHLKRFR HELMFSTKIS THVSFPLEGL DLQPFLAKDS PAQIVTYDLL
     SVICHHGTAS SGHYIAYCRN NLNNLWYEFD DQSVTEVSES TVQNAEAYVL FYRKSSEEAQ
     KERRRISNLL NIMEPSLLQF YISRQWLNKF KTFAEPGPIS NNDFLCIHGG VPPRKAGYIE
     DLVLMLPQNI WDNLYSRYGG GPAVNHLYIC HTCQIEAEKI EKRRKTELEI FIRLNRAFQK
     EDSPATFYCI SMQWFREWES FVKGKDGDPP GPIDNTKIAV TKCGNVMLRQ GADSGQISEE
     TWNFLQSIYG GGPEVILRPP VVHVDPDILQ AEEKIEVETR SL
//
